Clinical Outcomes in Toxoplasmic Retinochoroiditis: Comparing Intravitreal Clindamycin with and Without Adjunctive Steroids

PURPOSE: The goal was to compare the clinical characteristics and visual outcomes of patients treated with intravitreal clindamycin with and without adjunctive steroids for vision-threatening toxoplasmic retinochoroiditis. METHODS: A single-center retrospective cohort study of all toxoplasmic retinochoroiditis cases from January 1, 2013 to December 31, 2024 treated with intravitreal clindamycin was reviewed. Patients with vision-threatening disease and ≥3 months of follow-up data were included. Data collected included best-corrected visual acuity (BCVA), retinitis zone, aqueous and/or vitreous tap polymerase chain reaction results, number and type of intravitreal injections and systemic medications, complications and recurrence rates. CONCLUSIONS: Patients with toxoplasmic retinochoroiditis treated with intravitreal clindamycin had significantly improved BCVA. The addition of intravitreal or oral steroids did not have a statistically significant difference on vision or complication rates in this small retrospective cohort. No cases of injection-related endophthalmitis or lens injury were observed, but the small sample size limits conclusions regarding safety.